<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.4.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art540.dtd?><?SourceDTD.Version 5.4.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 2?><?origin publisher?><?FILEmeta_MOLCEL5914 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEfx1 jpg ?><?FILEmmc1 pdf ?><?FILEmmc2 xlsx ?><?FILEmmc3 xlsx ?><?FILEmmc4 xlsx ?><?FILEmmc5 xlsx ?><?FILEmmc6 xlsx ?><?FILEmmc7 xlsx ?><?FILEmmc8 xlsx ?><?FILEmmc9 pdf ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cell</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Cell</journal-id><journal-title-group><journal-title>Molecular Cell</journal-title></journal-title-group><issn pub-type="ppub">1097-2765</issn><issn pub-type="epub">1097-4164</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5003813</article-id><article-id pub-id-type="publisher-id">S1097-2765(16)30361-6</article-id><article-id pub-id-type="doi">10.1016/j.molcel.2016.07.008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Molecular Principles of Gene Fusion Mediated Rewiring of Protein Interaction Networks in Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Latysheva</surname><given-names>Natasha&#x000a0;S.</given-names></name><email>natashal@mrc-lmb.cam.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>Oates</surname><given-names>Matt&#x000a0;E.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Maddox</surname><given-names>Louis</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Flock</surname><given-names>Tilman</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Gough</surname><given-names>Julian</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Buljan</surname><given-names>Marija</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Weatheritt</surname><given-names>Robert&#x000a0;J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Babu</surname><given-names>M.&#x000a0;Madan</given-names></name><email>madanm@mrc-lmb.cam.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK</aff><aff id="aff2"><label>2</label>Department of Computer Science, University of Bristol, Bristol BS8 1UB, UK</aff><aff id="aff3"><label>3</label>The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>natashal@mrc-lmb.cam.ac.uk</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author <email>madanm@mrc-lmb.cam.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>8</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>18</day><month>8</month><year>2016</year></pub-date><volume>63</volume><issue>4</issue><fpage>579</fpage><lpage>592</lpage><history><date date-type="received"><day>12</day><month>4</month><year>2016</year></date><date date-type="rev-recd"><day>14</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>Gene fusions are common cancer-causing mutations, but the molecular principles by which fusion protein products affect interaction networks and cause disease are not well understood. Here, we perform an integrative analysis of the structural, interactomic, and regulatory properties of thousands of putative fusion proteins. We demonstrate that genes that form fusions (i.e., parent genes) tend to be highly connected hub genes, whose protein products are enriched in structured and disordered interaction-mediating features. Fusion often results in the loss of these parental features and the depletion of regulatory sites such as post-translational modifications. Fusion products disproportionately connect proteins that did not previously interact in the protein interaction network. In this manner, fusion products can escape cellular regulation and constitutively rewire protein interaction networks. We suggest that the deregulation of central, interaction-prone proteins may represent a widespread mechanism by which fusion proteins alter the topology of cellular signaling pathways and promote cancer.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple"><list-item id="u0010"><label>&#x02022;</label><p>Parents of fusion proteins occupy central positions in protein interaction networks</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>Parents are rich in interaction-mediating features, which are often lost via fusion</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>Fusions preferentially join proteins with no previous connection in protein networks</p></list-item><list-item id="u0025"><label>&#x02022;</label><p>Fusion proteins escape regulation by losing post-translational modification sites</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p>The molecular mechanisms of fusion-mediated interactome disruption are currently unclear. Latysheva et&#x000a0;al. find that fusion-forming proteins occupy central positions in interaction networks. They lose much of their extensive interaction-mediating ability and capacity for regulation upon fusion. These findings provide insights into how fusion proteins could rewire networks in cancer.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>gene fusion</kwd><kwd>fusion protein</kwd><kwd>cancer genomics</kwd><kwd>protein interaction networks</kwd></kwd-group></article-meta><notes><p id="misc0010">Published: August 18, 2016</p></notes></front><body><sec id="sec1"><title>Introduction</title><p>Fusion genes are hybrid genes formed from two previously independent parent genes. Historically, gene fusions have been viewed as common driver mutations in malignancies associated with blood, lymph, and bone marrow tissue, but are becoming increasingly recognized as important players in solid tumors (<xref rid="bib29" ref-type="bibr">Mertens et&#x000a0;al., 2015a</xref>, <xref rid="bib30" ref-type="bibr">Mertens et&#x000a0;al., 2015b</xref>, <xref rid="bib55" ref-type="bibr">Yoshihara et&#x000a0;al., 2015</xref>). For example, translocation-induced gene fusions are found in about 90% of all lymphomas and over half of all leukemias (<xref rid="bib27" ref-type="bibr">Lobato et&#x000a0;al., 2008</xref>), and the <italic>TMPRSS2-ERG</italic> fusion is the most frequent genetic aberration in prostate cancer (<xref rid="bib35" ref-type="bibr">Nam et&#x000a0;al., 2007</xref>). In accord with their important role in oncogenesis, fusion transcripts and proteins have been utilized in many areas of clinical care, from biomarker development and diagnostics to acting as therapeutic targets (<xref rid="bib25" ref-type="bibr">Kumar-Sinha et&#x000a0;al., 2015</xref>, <xref rid="bib30" ref-type="bibr">Mertens et&#x000a0;al., 2015b</xref>). Yet, aside from a relatively small number of well-studied fusions, the functions of fusion proteins and the cellular context in which they operate remain unclear.</p><p>A variety of mechanisms can lead to the fusion of two genes, such as insertions, deletions, inversions, and translocations. Continuous transcription of neighboring genes (<xref rid="bib46" ref-type="bibr">Varley et&#x000a0;al., 2014</xref>) or <italic>trans</italic>- and <italic>cis</italic>-splicing of pre-mRNAs (<xref rid="bib23" ref-type="bibr">Jividen and Li, 2014</xref>, <xref rid="bib57" ref-type="bibr">Zhang et&#x000a0;al., 2012</xref>) can also generate fusion transcripts and proteins. If fusion transcripts are translated, the resulting fusion proteins have the potential to redirect cellular signaling pathways and act as principal oncogenic drivers (see <xref rid="bib52" ref-type="bibr">Watson et&#x000a0;al., 2013</xref>, <xref rid="bib55" ref-type="bibr">Yoshihara et&#x000a0;al., 2015</xref>). Despite some concerns over whether certain putative fusion mRNAs may be artifacts of the sequencing procedure (<xref rid="bib56" ref-type="bibr">Yu et&#x000a0;al., 2014</xref>), the widespread finding of recurrent gene fusions in tumor samples, the clinical utility of an increasing number of gene fusions, and a growing body of literature on fusion protein functionality adds support to their potential for significant biological impact.</p><p>There are now approximately 10,000 known gene fusions, most of which have only recently been discovered using deep sequencing technology (<xref rid="bib29" ref-type="bibr">Mertens et&#x000a0;al., 2015a</xref>). The molecular functions of gene fusions, and the fusion proteins they encode, remain relatively poorly understood. Recent bioinformatics work on gene fusions (reviewed in <xref rid="bib26" ref-type="bibr">Latysheva and Babu, 2016</xref>) has examined fusion protein domain content and recombination, reading frame conservation, intrinsic disorder at fusion junctions, and expression properties. However, the molecular principles of fusion-mediated rewiring of protein networks and how fusion proteins could disrupt native protein interactions remain unclear. Here, we devise a genome-scale computational data analysis framework to investigate the molecular principles by which fusion proteins affect protein interactions (<xref rid="fig1" ref-type="fig">Figures 1</xref>A and 1B). Understanding the structural features of fusion proteins, as well as the interactions that are recurrently disrupted or created as a result of fusion, will help clarify how fusions contribute to specific cellular phenotypes and influence cancer initiation and progression.</p></sec><sec id="sec2"><title>Results</title><p>To compose a set of human fusion proteins, a list of fusion transcripts from the ChiTaRS v1 database (<xref rid="bib15" ref-type="bibr">Frenkel-Morgenstern et&#x000a0;al., 2013</xref>) was acquired and mapped onto Ensembl protein sequences (<xref rid="sec4" ref-type="sec">Experimental Procedures</xref>; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). In this study, only fusions affecting protein-coding regions were examined. In total, we mapped 2,699 distinct fusion proteins derived from 3,279 genes (<xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>; fusion protein mappings are available as a web resource at <ext-link ext-link-type="uri" xlink:href="http://fusion.d2p2.pro" id="intref0010">http://fusion.d2p2.pro</ext-link>, integrated into the D2P2 database; <xref rid="bib36" ref-type="bibr">Oates et&#x000a0;al., 2013</xref>). Genes that form fusions (&#x0201c;parent genes&#x0201d;) are enriched for functions related to translation, mRNA splicing, and the cell cycle, and for protein classes related to translation, acetyltransferase activity, and the binding of actin, chromatin, and RNA (<xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>). Parent genes that form multiple fusions, especially five or more, are further enriched for functions relating to translation, RNA binding, and nucleic acid binding.</p><p>Gene fusion events can be summarized as a network, in which nodes indicate genes and a link between nodes indicates the occurrence of a fusion between genes. Our resulting network of gene fusions involving 3,209 genes (as gene symbols; <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>A) expands upon previous networks of &#x0223c;300 gene fusions (<xref rid="bib19" ref-type="bibr">H&#x000f6;glund et&#x000a0;al., 2006</xref>, <xref rid="bib34" ref-type="bibr">Mitelman et&#x000a0;al., 2007</xref>); we confirm the presence of several major hubs, i.e., nodes with many edges (e.g., <italic>MLL</italic>, <italic>ETV6</italic>, <italic>NUP98</italic>, <italic>EWSR1</italic>, and <italic>ALK</italic>), and highlight novel fusion hubs (e.g., <italic>COL1A1</italic>, <italic>HSP90AA1</italic>, <italic>MT1A</italic>, <italic>NCL</italic>, and <italic>AFF1</italic>; <xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>; <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>A). The number of fusions formed for each gene follows a power law distribution (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>B), with most parent genes forming few fusions (e.g., only 21 genes form ten or more fusion proteins). Over a third of known oncogenes (OGs) and a quarter of known tumor suppressor genes (TSGs) form fusions in this data set (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>).</p><sec id="sec2.1"><title>Parent Proteins Have More Central Roles in Protein Interaction Networks and Are Expressed at Higher Levels</title><p>To examine whether parent genes encode proteins with central positions in the human interactome, a high-confidence data set of human protein-protein interactions (PPIs) (<xref rid="bib50" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>) was analyzed. In addition to a much higher number of interaction partners (node degree; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A), parent proteins have a significantly higher tendency to interconnect interaction clusters, as quantified by betweenness centrality, which measures the extent to which a given node in a network lies on the shortest paths between all other nodes (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B). Furthermore, parent proteins have higher Kleinberg&#x02019;s hub scores (see <xref rid="sec4" ref-type="sec">Experimental Procedures</xref>), which measure a protein&#x02019;s connection to network hubs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). Compared to central non-parents, the most central parent proteins were more likely to be involved in functions such as mRNA splicing, cell proliferation, DNA replication, and repair (<xref rid="mmc3" ref-type="supplementary-material">Table S2</xref>).</p><p>We observed that parent mRNAs and proteins are more abundant compared to non-parents (&#x0223c;3-fold difference between averages; <xref rid="mmc1" ref-type="supplementary-material">Figures S2</xref>A and S2B) in medulloblastoma cell lines (<xref rid="bib48" ref-type="bibr">Vogel et&#x000a0;al., 2010</xref>). Additionally, parent proteins have very similar half-lives to non-parent proteins (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>C). Further, by integrating data on 12 oncogenic signaling blocks (<xref rid="bib9" ref-type="bibr">Cui et&#x000a0;al., 2007</xref>), we find that parent proteins are over twice as likely to be involved in signaling processes implicated in oncogenesis (&#x003c7;<sup>2</sup>&#x000a0;= 29.5, df&#x000a0;= 1, and p&#x000a0;= 5.7&#x000a0;&#x000d7; 10<sup>&#x02212;8</sup>) (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>D) and are over 2.5 times as likely to be genes essential for cellular viability (&#x003c7;<sup>2</sup>&#x000a0;= 396.8, df&#x000a0;= 1, and p&#x000a0;&#x0003c; 2.2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>) (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>E). Although these trends need to be analyzed in different tissues, these results suggest that altering parent proteins could have a major effect on critical cellular functions and for a sustained period of&#x000a0;time.</p><p>Parent genes were grouped into OG parent genes, TSG parent genes, and all other parent genes (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>A). Parent genes that are neither OGs nor TSGs possess significantly higher network centrality than non-parent genes, indicating that centrality is a feature of parent genes more broadly and not simply reflective of the centrality of OGs and TSGs. Further, parent OGs and TSGs tend toward higher centrality than non-parent OGs and TSGs, respectively (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>B). For example, average centrality measures for parent TSGs are approximately 30% higher than non-parent TSGs. Replicate network centrality calculations on two additional PPI data sets&#x02014;the consensus network used in further analyses (see below; <xref rid="bib5" ref-type="bibr">Bossi and Lehner, 2009</xref>) (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>C) and an unbiased interaction network derived using mass spectrometry (<xref rid="bib21" ref-type="bibr">Huttlin et&#x000a0;al., 2015</xref>) (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>D)&#x02014;were consistent with those described above.</p></sec><sec id="sec2.2"><title>Parent Proteins Have Higher Centrality in the Interaction Networks of Cancer-Associated Cell and Tissue Types</title><p>Next, the role of parent proteins in tissue-specific protein interaction networks (<xref rid="bib5" ref-type="bibr">Bossi and Lehner, 2009</xref>) was examined. PPIs involving parent proteins are present in more human tissues (median of 64 of 79 tissues, compared to 52 of 79 for non-parents; p&#x000a0;&#x0003c; 2.2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D), indicating that fusion events do not only affect tissue-specific interactions. Parent proteins consistently have on average &#x0223c;5 additional interaction partners across most tissues (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E). Interestingly, the tissues and cell types with the highest degrees for parent proteins&#x02014;e.g., B&#x000a0;and T&#x000a0;cells, bone marrow cells, and blood cells&#x02014;are cell types often associated with fusion-induced cancers (gold dots, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E). Furthermore, parent proteins in the five cancer cell types in the data set (teal dots) have on average 9.1% higher degree than non-cancer cells and 12.1% higher degree than the set of non-cancer and non-blood/bone/lymph cell types (<xref rid="mmc4" ref-type="supplementary-material">Table S3</xref>). This trend is not observed for betweenness (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>E), but is for hub scores (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>F), which may indicate that gene fusions in cancer may preferentially affect nodes of high degree (either directly or indirectly) rather than alter global network cohesion. Fusions could therefore be especially disruptive in tissues with interaction networks containing proteins with unusually high degree. Finally, fusion transcripts detected in cell lines of metastatic tumor origin may have parent genes with higher centrality compared to those from primary tumors (<xref rid="mmc1" ref-type="supplementary-material">Figures S4</xref>A&#x02013;S4D; <xref rid="app2" ref-type="sec">Supplemental Information</xref>), suggesting a possible connection between cancer aggressiveness and parent centrality. Although this trend was not observed in the mass spectrometry PPI data set (<xref rid="bib21" ref-type="bibr">Huttlin et&#x000a0;al., 2015</xref>; data not shown), the concept of a link between cancer stage and the roles of parent proteins in PPI networks may be relevant in specific contexts (e.g., certain cancer types).</p></sec><sec id="sec2.3"><title>Parent Proteins Are Unstructured and Enriched for Interaction-Mediating Domains, which Are Preferentially Excluded from Fusion Proteins</title><p>The structural features of parent proteins and their retention within fusion proteins were investigated (<xref rid="fig3" ref-type="fig">Figures 3</xref>A&#x02013;3L and <xref rid="mmc1" ref-type="supplementary-material">S5</xref>A&#x02013;S5K). In agreement with a previous study (<xref rid="bib18" ref-type="bibr">Hegyi et&#x000a0;al., 2009</xref>), parent proteins in our expanded data set (3,279 parent proteins versus 406) have significantly higher intrinsic structural disorder scores than non-parents (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>A): OG parents have on average 1.27&#x000a0;&#x000d7; (0.39 versus 0.31; p&#x000a0;= 2.8&#x000a0;&#x000d7; 10<sup>&#x02212;4</sup>; and pairwise Wilcoxon rank-sum tests with Holm multiple testing correction), TSG parents 1.15&#x000a0;&#x000d7; (p&#x000a0;= 1.5&#x000a0;&#x000d7; 10<sup>&#x02212;3</sup>), and other parents 1.13&#x000a0;&#x000d7; (p&#x000a0;&#x0003c; 2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>) higher disorder compared to non-parents. Parent OGs and TSGs are approximately equally disordered as non-parent OGs and TSGs (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>B), as are included versus excluded fusion protein segments (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>C). This suggests that any observed enrichment of linear motifs and post-translational modifications (PTMs) in included segments (see below), which are features correlated with disorder (<xref rid="bib10" ref-type="bibr">Davey et&#x000a0;al., 2012</xref>), are not simply due to included segments being more disordered. Throughout the structural feature calculations, densities instead of counts are used to control for protein length.</p><p>Using a database of PPIs defined at the structurally resolved level of domains (<xref rid="bib31" ref-type="bibr">Meyer et&#x000a0;al., 2013</xref>), we investigated parent versus non-parent densities of interaction-mediating domains (IMDs). Parent proteins, especially OG and TSG parent proteins, have higher densities of IMDs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). On average, compared to non-parent proteins, OG parents have 4.6&#x000d7;, TSG parents 2.7&#x000d7;, and other parents 1.5&#x000d7; the IMD densities (all corrected p values: &#x0003c;2.2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>). There is a slight tendency for parent OGs to have higher IMD densities than non-parent OGs (on average 1.3&#x000d7;; p&#x000a0;= 9.1&#x000a0;&#x000d7; 10<sup>&#x02212;3</sup>; <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>D). Hence, although parent proteins are generally more intrinsically disordered, they are also enriched in structured domains that mediate protein interactions. IMDs tend to largely be excluded from fusion proteins (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B; <xref rid="mmc5" ref-type="supplementary-material">Table S4</xref>). OG parent proteins, in contrast to TSG and other parent proteins, tend to retain IMDs upon fusion. Overall, the most frequently retained IMDs include RNA-recognition, tyrosine kinase, pleckstrin homology (signaling and cytoskeleton), and SH3 and SH2 signaling domains (<xref rid="mmc5" ref-type="supplementary-material">Table S4</xref>). The&#x000a0;average level of domain truncation upon transfer varies significantly by domain type, and the most intact IMDs which occur &#x02265;10 times include ubiquitin conjugating domains, the ubiquitin-like PB1 domain (a specificity adaptor to kinases), and the proliferation modulating S_100 domain. Parents that repeatedly donate large portions of IMDs are enriched for functions in translation, cell structure morphogenesis, and cell cycle and protein modification (<xref rid="mmc5" ref-type="supplementary-material">Table S4</xref>).</p></sec><sec id="sec2.4"><title>Transfer of IMDs Can Create Novel Interactions and Preserve Important Natural Interactions</title><p>The repeated inclusion of large portions of specific IMDs in fusion proteins is interesting for two reasons (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). First, it can point to the importance of a particular domain-domain interaction (DDI) for a fusion protein&#x02019;s function. Second, as a result of the fusion, a novel interaction-like link can occur between the interaction partner of the included domain and the fusion partner. We map which domain-mediated PPIs are repeatedly conserved in fusion proteins (<xref rid="fig4" ref-type="fig">Figures 4</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S6</xref>A; <xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>). We find that 192 IMD-mediated PPIs are recurrently retained in fusion proteins and comment on the most frequently conserved DDIs (see the <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>A legend).</p><p>We also map novel protein links that are created through IMD transfer (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and <xref rid="mmc1" ref-type="supplementary-material">S6</xref>B; <xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>). A protein interaction &#x0201c;link&#x0201d; was drawn between proteins A and B if there existed some fusion protein B-C, where C normally interacts with A and at least 90% of C&#x02019;s IMD was retained (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). Of the 126 novel links, 116 (92%) do not normally occur in the cell. The most frequent novel links include many connections for BCR, with the newly linked proteins being enriched for functions in cell proliferation and cellular component movement (<xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>), and 11 new connections for the nuclear trafficking protein TPR, including eight tyrosine protein phosphatases (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and <xref rid="mmc1" ref-type="supplementary-material">S6</xref>B). Certain fusion-induced novel links are recurrent, e.g., fusion proteins involving both EML4 and TFG lead to the gain of similar links (i.e., connections to receptor-type protein tyrosine phosphatases PTPRB, PTPRG, and PTPRJ).</p></sec><sec id="sec2.5"><title>Fusion-Generated Novel Links Disproportionately Connect Proteins that Are Distant in the Interaction Network</title><p>We examined the distance between the protein pairs in the novel links set in a non-diseased PPI network. Where a path existed between the novel links pairs, the distance was overall slightly shorter than in other protein pairs in the network (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>C). However, fusion was found to disproportionately connect proteins which normally reside in separate sections of the interactome, whereas only 10.7% of protein pairs in the PPI network had no connecting path, 29.3% of protein pairs in the novel links set had no previous connecting path (Fisher&#x02019;s exact test on contingency table, odds ratio&#x000a0;= 3.47, p&#x000a0;= 3.0&#x000a0;&#x000d7; 10<sup>&#x02212;8</sup>) (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>D). We examine the 34 newly connected protein pairs in <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>E (see the legend).</p></sec><sec id="sec2.6"><title>Independent Structural Evidence Supports the Potential of Fusion Proteins to Disrupt PPI, Protein-RNA Interactions, and Protein-DNA Interactions</title><p>Structural interfaces in fusion proteins were identified by analyzing the Protein Interfaces, Surfaces, and Assemblies (PISA) database, which houses macromolecular interfaces (involving proteins, RNA, and DNA) in the Protein Data Bank (PDB). Parent proteins in the PDB contain more interface-forming residues (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). On average, 1.5% of residues in non-parents form interfaces, and OG parents have on average 4.5&#x000d7;, TSG parents 2.1&#x000d7;, and other parents 2.0&#x000d7; this PISA residue density. Parent OGs have 2.4&#x000d7; the average interface residue density of non-parent OGs (p&#x000a0;= 3.6&#x000a0;&#x000d7; 10<sup>&#x02212;5</sup>; <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>E). Interface residue densities on included and excluded segments of parent proteins are similar (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D), though the distribution is skewed toward exclusion (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>F). The 302 parent proteins which donate ten or more interface-forming residues to fusion proteins are enriched for functions relating to cell cycle signaling, carbohydrate and lipid metabolism, cellular component morphogenesis, and cell death (<xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>).</p></sec><sec id="sec2.7"><title>Parent Proteins Are Enriched in Interaction-Mediating Short Linear Motifs, which May Be Preferentially Excluded from Fusion Products</title><p>Linear motifs (LMs) are short sequence motifs, usually &#x0003c;10 residues, often found in intrinsically disordered regions (<xref rid="bib44" ref-type="bibr">Tompa et&#x000a0;al., 2014</xref>). Using 1,410 experimentally validated LMs from the ELM database (<xref rid="bib12" ref-type="bibr">Dinkel et&#x000a0;al., 2014</xref>) and over a million putative LMs identified using the ANCHOR program (<xref rid="bib14" ref-type="bibr">Doszt&#x000e1;nyi et&#x000a0;al., 2009</xref>), we tested for enrichment of LMs within parent proteins compared to all other proteins. Parent proteins have more experimentally verified LMs on average (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E), with OG and TSG parents harboring more motifs. Although most parents have zero experimental LMs due to the small size of this data set, on average, OG parents have 10.1&#x000d7; (p&#x000a0;&#x0003c; 2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>), TSG parents 7.1&#x000d7; (p&#x000a0;&#x0003c; 2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>), and other parents 1.3&#x000d7; (p&#x000a0;= 8.0&#x000a0;&#x000d7; 10<sup>&#x02212;10</sup>) the LM density of non-parents. Parent TSGs have slightly higher LM densities compared to non-parent TSGs (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>G). Fusion proteins tend to retain ELM LMs, as shown by higher mean LM densities in included segments (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>F). Parent proteins, which donate ELM LMs, function in the regulation of cell death, the stress response, protein metabolism, and nucleic acid binding (<xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>). Similarly, the expanded ANCHOR data shows higher densities of LMs in parents (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G), though parent OGs and TSGs have similar densities to the non-parent categories (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>H). Interestingly, the larger ANCHOR data set shows a strong trend toward the exclusion of LMs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>H). Either trend implies that fusion substantially disrupts transient interactions mediated by LMs.</p></sec><sec id="sec2.8"><title>PTMs that Regulate Protein Interactions Are Enriched in Parent Proteins</title><p>We mapped putative interaction-regulating PTMs (PTMcode v2 database; <xref rid="bib33" ref-type="bibr">Minguez et&#x000a0;al., 2015</xref>) onto proteins and found that compared to non-parents, OG parents have on average 4.6&#x000d7;, TSG parents 3.5&#x000d7;, and other parents 2.2&#x000d7; the PTM density (all corrected p&#x000a0;&#x0003c; 2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>I). Parent TSGs have slightly more interaction-regulating PTMs compared to non-parent TSGs (1.5&#x000d7;, p&#x000a0;= 0.03; <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>I). These PTM sites overall tend toward exclusion from fusion proteins (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>J), though the retention and loss is comparable in OG and TSG parents.</p></sec><sec id="sec2.9"><title>Parent Proteins Are Enriched in PTM Sites, and Fusion Proteins Tend to Selectively Escape Regulation by PTMs</title><p>In addition to regulating protein interactions, post-translational and co-translational modification sites can regulate protein stability (e.g., by ubiquitination), subcellular localization (e.g., N-myristoylation), and protein function (e.g., acetylation). Parent proteins have significantly more PTMs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>J) compared to non-parents (on average 0.009 PTMs/residue): OG parents have 3.5&#x000d7;, TSG parents 3.5&#x000d7;, and other parents 2.3&#x000d7; the PTM densities of non-parents (all corrected p&#x000a0;&#x0003c; 2&#x000a0;&#x000d7; 10<sup>&#x02212;16</sup>). This suggests that the function, stability, and subcellular location of parent proteins are extensively regulated by PTMs. Further, on average, parent OGs have 1.5&#x000d7; (p&#x000a0;= 7.5&#x000a0;&#x000d7; 10<sup>&#x02212;3</sup>) the PTM content of non-parent OGs, and parent TSGs have 2.1&#x000d7; (p&#x000a0;= 1.4&#x000a0;&#x000d7; 10<sup>&#x02212;5</sup>) the PTM content of non-parent TSGs (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>K). PTMs are generally excluded from fusion proteins, though not in OG parents (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>K). The selective exclusion of PTM sites suggests that fusion proteins tend to escape regulation by signaling pathways. TSG parents experience the heaviest loss of PTMs, with excluded segments having over triple the median PTM density of included segments (excluded: 0.022 PTMs/residue; included: 0.007; p&#x000a0;= 3.0&#x000a0;&#x000d7; 10<sup>&#x02212;4</sup>; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>K). Parent proteins which retain at least 90% of their PTM content are enriched for functions in translation, ion transport, and metabolism (<xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>), while parent proteins which lose at least 90% of their PTMs have a wide range of functions, including splicing and cell matrix adhesion.</p><p>Next, we examined the PTM profiles in included and excluded fusion protein segments (<xref rid="sec4" ref-type="sec">Experimental Procedures</xref>; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>L). Certain PTM types (e.g., S-Nitrosylation) occur in either parental segment more frequently than expected given the global frequencies of all PTMs in dbPTM, while other PTM types (e.g., methylation and acetylation) showed marked presence/absence patterns based on segment inclusion (<xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>).</p></sec><sec id="sec2.10"><title>Fusion Can Lead to the Gain and Loss of Ubiquitination Sites, which May Deregulate the Activity of OGs and&#x000a0;TSGs</title><p>Ubiquitination (UB) sites are of particular interest since their loss and gain upon fusion could &#x0201c;upregulate&#x0201d; OG activity or &#x0201c;downregulate&#x0201d; TSG activity, due to the role of UB sites in mediating protein stability and degradation. We find 14 fusion proteins in which OGs lose &#x02265;5&#x000a0;UB sites and ten fusion proteins in which a TSG gains &#x02265;5&#x000a0;UB sites (<xref rid="tbl1" ref-type="table">Table 1</xref>). As an illustrative example, we profile the well-known <italic>EWSR1-FLI1</italic> gene fusion from Ewing&#x02019;s sarcoma (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). The specific pattern of segment retention in EWSR1-FLI1 fusion proteins leads to UB site loss, which may confer increased stability onto the fusion product, adding to the known oncogenic mechanism of transcriptional deregulation. Notably, decreased UB-mediated degradation of ETS family transcription factors (e.g., FLI1) has been linked to cancer (<xref rid="bib47" ref-type="bibr">Vitari et&#x000a0;al., 2011</xref>). Conversely, one of the most extreme examples of UB site gain by a TSG occurs in the previously unstudied <italic>ATP50-TGFB1</italic> fusion (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B), which results in the amalgamation of a heavily ubiquitinated segment with a short portion of the TGFB1 tumor suppressor domain, hinting at a fusion-mediated loss of TSG function. TGF-&#x003b2; signaling is known to inhibit cell proliferation and is normally tightly regulated by UB (<xref rid="bib20" ref-type="bibr">Huang and Chen, 2012</xref>). OG parents do not lose and TSG parents do not gain UB sites more often than expected (data not shown), but individual cases identified here (<xref rid="tbl1" ref-type="table">Table 1</xref>) could be of substantial biological interest for follow-up studies.</p></sec><sec id="sec2.11"><title>Fusions Involving Transcription Factors Are Linked to Significant Alterations in Downstream Target Gene Expression Levels</title><p>To investigate the potential downstream network rewiring effects due to fusion events, we investigated whether fusions involving transcription factors (TFs) are associated with downstream expression changes in the TFs&#x02019; regulatory targets. TCGA tumor samples with TF-containing fusion transcripts and paired normal controls were identified (<xref rid="sec4" ref-type="sec">Experimental Procedures</xref>). The regulatory target genes of TFs were acquired from the TRRUST database (<xref rid="bib17" ref-type="bibr">Han et&#x000a0;al., 2015</xref>). Differential gene expression (DGE) values were calculated (absolute log<sub>2</sub> fold change between diseased and healthy samples). The targets of TFs had significantly (i.e., corrected p&#x000a0;&#x0003c; 0.05) higher DGE values in five of the eight paired breast cancer samples when compared to all other genes (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S7</xref>). For example, four fusion transcripts containing TFs were detected in patient TCGA-GI-A2C9; these four TFs together affected 51 mapped regulatory targets, the mean (absolute log<sub>2</sub>) DGE of which is 2.0&#x000d7; the mean DGE of all other genes (<xref rid="mmc8" ref-type="supplementary-material">Table S7</xref>; corrected p&#x000a0;= 9.6&#x000a0;&#x000d7; 10<sup>&#x02212;5</sup>). Across the eight available biospecimen pairs, the average DGE of TF targets is 1.41&#x000d7; (mean) and 1.45&#x000d7; (median) the DGE of all other genes.</p></sec></sec><sec id="sec3"><title>Discussion</title><p>Many disease states result from altered dynamics of complex regulatory and signaling interactions. Representing interactions as networks provides a conceptual framework for understanding how mutations in proteins can affect entire cellular systems and cause disease (<xref rid="bib49" ref-type="bibr">Wang et&#x000a0;al., 2011</xref>, <xref rid="bib54" ref-type="bibr">Wu et&#x000a0;al., 2010</xref>), especially when combined with structural analyses of interacting proteins (<xref rid="bib41" ref-type="bibr">Sudha et&#x000a0;al., 2014</xref>, <xref rid="bib50" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>). Here, we investigated the interaction properties and structural features of thousands of putative fusion proteins. Based on our observations, we delineate genome-scale molecular principles by which gene fusions can affect protein networks, rewire signaling pathways, and contribute to disease (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>). These trends will be useful for setting novel gene fusions into context, building on the performance of previous driver gene fusion prioritization algorithms (<xref rid="bib1" ref-type="bibr">Abate et&#x000a0;al., 2014</xref>, <xref rid="bib40" ref-type="bibr">Shugay et&#x000a0;al., 2013</xref>), and interpreting studies of fusion protein functionality.</p><sec id="sec3.1"><title>Fusion Preferentially Affects Highly Central, Interaction-Prone Proteins</title><p>Although it is likely that not all of the analyzed fusion proteins drive disease (e.g., genomic instability can produce passenger fusions; <xref rid="bib29" ref-type="bibr">Mertens et&#x000a0;al., 2015a</xref>), parent proteins are nonetheless enriched for a wide variety of interaction-prone elements, such as IMDs, interface-forming residues, LMs, and PTM sites that regulate PPIs. The observed density of interaction-mediating features in parent proteins is in accord with their centrality in interaction networks. These results are consistent with other computational work on disease mutations, which have shown that disease-related in-frame mutations (<xref rid="bib50" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>) and disease-causing non-synonymous single nucleotide polymorphisms (<xref rid="bib11" ref-type="bibr">David et&#x000a0;al., 2012</xref>) are preferentially located on PPI interfaces. Finally, the finding that many parent genes are essential genes dovetails with the concept of &#x0201c;edgetic&#x0201d; perturbations in cancer, i.e., mutations that disrupt specific interactions (or edges) of proteins rather than the entire node (<xref rid="bib7" ref-type="bibr">Charloteaux et&#x000a0;al., 2011</xref>, <xref rid="bib39" ref-type="bibr">Rolland et&#x000a0;al., 2014</xref>, <xref rid="bib51" ref-type="bibr">Wang et&#x000a0;al., 2015</xref>), given that disrupting essential genes is associated with lethality, fusion may offer an opportunity to disrupt only a portion of an essential protein&#x02019;s function, such as specific interactions.</p><p>Network disruption may play a role in fusion proteins that first appear to have relatively simple mechanisms of oncogenesis (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A), for example, the concurrent rewiring of signaling pathways can be critical for BCR-ABL1 mediated transformation (<xref rid="bib37" ref-type="bibr">Pawson and Warner, 2007</xref>). Importantly, targeting the interacting partners or downstream signaling of fusion proteins could be a fruitful area for therapeutic agent development (see <xref rid="bib42" ref-type="bibr">Tognon et&#x000a0;al., 2011</xref>). In this context, our observation that TF fusions significantly perturb target gene expression in breast cancer lends further weight to the signaling perturbation capabilities of fusion events.</p></sec><sec id="sec3.2"><title>Fusion Results in a Loss of Parental Interaction-Mediating Features and Regulatory Sites</title><p>Although parent proteins are enriched for interaction-mediating features, the segments of parents that are included within fusion proteins appear to be depleted of functional regions (though OG&#x000a0;parents retain more of these features than other parents). Examining specific cases of fusion-mediated loss and gain of molecular features (<xref rid="fig3" ref-type="fig">Figures 3</xref>A&#x02013;3L), as well as interaction preservation and creation (<xref rid="fig4" ref-type="fig">Figures 4</xref>A&#x02013;4C), is a rich resource for hypothesis generation. For example, fusion proteins characterized by the repeated inclusion of largely complete tyrosine kinase domains (e.g., <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B) could be promising targets for kinase inhibitors. Proteins dependent on the function of several distinct molecular features (such as the interface residues and nuclear import/export signal motifs in nucleophosmin; <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B), as well as proteins sensitive to changes in PTM content (such as EWSR1; <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C), may be especially disrupted by fusion events.</p><p>Although we largely addressed each interaction-mediating and regulatory molecular feature of parent and fusion proteins separately, these entities are not independent. For instance, LMs tend to form interactions conditionally on PTM site status (<xref rid="bib45" ref-type="bibr">Van Roey et&#x000a0;al., 2013</xref>). For example, the retinoic receptor alpha gene (<italic>RAR&#x003b1;</italic>) encodes a LM that acts as a phosphorylation-dependent switch for binding Pin1. RAR&#x003b1; forms driver fusion proteins in acute promyelocytic leukemia, for which Pin1 suppression is used as a treatment (<xref rid="bib16" ref-type="bibr">Gianni et&#x000a0;al., 2009</xref>). We find a RAR&#x003b1; fusion protein that excludes the LM in question (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C), which could correspond to a treatment resistant patient. Knowledge of the specific retained sequence of fusion proteins has previously been observed to be key to patient treatment (<xref rid="bib38" ref-type="bibr">Robinson et&#x000a0;al., 2011</xref>).</p></sec><sec id="sec3.3"><title>Conclusions</title><p>Our findings demonstrate that proteins that form fusions tend to be highly interactive and positioned in critical regions of PPI networks. Disruption of such proteins may alter the topology of signaling and regulatory pathways of cells and promote cancer. A detailed understanding of the molecular impact of the rewired network will be helpful for future drug discovery studies. For example, in cases where driver fusion proteins retain the ability to form interactions, their carcinogenic activity could be reduced by the targeted disruption of specific interaction interfaces with small molecules (<xref rid="bib8" ref-type="bibr">Cierpicki and Grembecka, 2015</xref>, <xref rid="bib22" ref-type="bibr">Jin et&#x000a0;al., 2014</xref>, <xref rid="bib24" ref-type="bibr">Kuenemann et&#x000a0;al., 2015</xref>). Additionally, recent methodological advances in therapeutically degrading specific proteins in&#x000a0;vivo (<xref rid="bib4" ref-type="bibr">Bondeson et&#x000a0;al., 2015</xref>, <xref rid="bib53" ref-type="bibr">Winter et&#x000a0;al., 2015</xref>) could be instrumental to targeting oncogenic fusion proteins that have escaped normal regulatory pathways.</p></sec></sec><sec id="sec4"><title>Experimental Procedures</title><sec id="sec4.1"><title>Database Identification, Processing, and Integration</title><p>To compose a set of human fusion proteins, we acquired a database (ChiTaRS v1 database; <xref rid="bib15" ref-type="bibr">Frenkel-Morgenstern et&#x000a0;al., 2013</xref>) of 9,237 fusion mRNAs. The fusion transcripts were mapped onto known proteins in the Ensembl database using ChiTaRS genomic coordinates and segments that mapped to non-exonic regions (intronic, UTR, or intergenic sequences) were discarded. The resulting data set maps all fusion protein segments defined at the DNA/gene, mRNA, and protein levels (<xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>). We limit our analysis to fusion proteins in which both parents were mapped to known Ensembl proteins. Fusion protein mapping information is made available via a web server (<ext-link ext-link-type="uri" xlink:href="http://www.fusion.d2p2.pro" id="intref0015">http://www.fusion.d2p2.pro</ext-link>). A fusion network of all gene fusions was constructed using Cytoscape. Throughout this study, gene sets were tested for enrichments of GO-Slim molecular functions and protein classes using PantherDB (<xref rid="bib32" ref-type="bibr">Mi et&#x000a0;al., 2013</xref>). See the <xref rid="app2" ref-type="sec">Supplemental Information</xref> for further methodological details.</p></sec><sec id="sec4.2"><title>mRNA and Protein Abundance and Half-Lives of Parents</title><p>Protein and mRNA abundances were acquired from a microarray and shotgun proteomics study performed on the Daoy medulloblastoma cell line (<xref rid="bib48" ref-type="bibr">Vogel et&#x000a0;al., 2010</xref>), and protein half-life data were taken from a SILAC study in HeLa cells (<xref rid="bib3" ref-type="bibr">Boisvert et&#x000a0;al., 2012</xref>). These data sets were overlapped onto parent and non-parent gene sets, and differences in distributions of abundance and half-life by category were quantified by non-parametric Wilcoxon rank-sum tests.</p></sec><sec id="sec4.3"><title>Parent Gene Participation in Oncogenic Signaling Blocks</title><p>Disproportionate parent protein participation in cancer signaling processes (<xref rid="bib9" ref-type="bibr">Cui et&#x000a0;al., 2007</xref>) was assessed using a contingency table and a chi-square test of independence.</p></sec><sec id="sec4.4"><title>Parent Gene Essentiality</title><p>1,734 &#x0201c;core&#x0201d; essential genes shared between two cell lines (<xref rid="bib2" ref-type="bibr">Blomen et&#x000a0;al., 2015</xref>) were acquired and tested for enrichment among parent genes as above.</p></sec><sec id="sec4.5"><title>PPI Network Centrality</title><p>Network centrality calculations for both parent and non-parent genes/proteins were performed on a non-tissue specific PPI network (<xref rid="bib50" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>) using the igraph R package. See the <xref rid="app2" ref-type="sec">Supplemental Information</xref> for definitions of centrality measures. A tissue-specific PPI network (<xref rid="bib5" ref-type="bibr">Bossi and Lehner, 2009</xref>) was acquired in order to calculate tissue-specific PPI metrics (<xref rid="bib6" ref-type="bibr">Buljan et&#x000a0;al., 2012</xref>). A more recent, expanded, and unbiased protein interaction data set from human cells (<xref rid="bib21" ref-type="bibr">Huttlin et&#x000a0;al., 2015</xref>) was also investigated.</p></sec><sec id="sec4.6"><title>Intrinsic Structural Disorder in Parent Proteins</title><p>Residue-by-residue predictions for disorder for each protein in the human proteome were generated using the IUPred program (<xref rid="bib13" ref-type="bibr">Doszt&#x000e1;nyi et&#x000a0;al., 2005</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.iupred.enzim.hu/" id="intref0020">http://www.iupred.enzim.hu/</ext-link>). Scores range from 0 to 1, where higher scores indicate a higher propensity toward intrinsic disorder. Intrinsic disorder was calculated for genes (i.e., longest isoform Ensembl protein) and for specific included and excluded segments as an average over either the protein or segment length.</p></sec><sec id="sec4.7"><title>Analysis of Interacting Domains within Proteins</title><p>A data set of curated, structurally resolved PPIs was acquired (<xref rid="bib31" ref-type="bibr">Meyer et&#x000a0;al., 2013</xref>), and residues that form IMDs were mapped onto parent and non-parent proteins. IMD retention was quantified by calculating IMD residue densities on included and excluded segments. The frequency and completeness of retention of different domain types was summarized across the fusion protein set. Statistically significant differences between gene sets in the distributions of IMD residues were assessed as before. Parents which donate &#x02265;20% of at least one IMD were analyzed for functional and protein class enrichments.</p></sec><sec id="sec4.8"><title>Identifying Novel and Retained PPIs of Fusion Proteins</title><p>The above set of domain-mediating PPIs was analyzed to identify which PPIs are recurrently (two or more times) retained in fusion proteins. DDIs were deemed to be &#x0201c;retained&#x0201d; if at least one fusion protein incorporated at least 90% of the IMD. Novel interactions created as a result of the transfer of IMDs were between protein A and B if there existed at least one fusion protein B-C, where C normally interacts with A and at least 90% of C&#x02019;s IMD was retained. Novel links were those that did not appear in a set of known PPIs (<xref rid="bib50" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>).</p></sec><sec id="sec4.9"><title>Identifying Shortest Path Distances between Proteins Newly Linked by Fusion</title><p>Pairwise shortest path lengths (geodesics) between all protein pairs in a PPI network (<xref rid="bib50" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>) were calculated using igraph. The distribution of shortest path lengths in the novel link set was compared to the distribution of path lengths in 1,000 randomly sampled protein pairs from the complete geodesic matrix as before. Disconnected protein pairs had infinite shortest path lengths, reflecting the absence of a geodesic. A contingency table containing the counts of disconnected novel links versus other disconnected protein pairs was constructed and tested for independence using Fisher&#x02019;s exact test.</p></sec><sec id="sec4.10"><title>Analysis of Interaction Interfaces in Parents</title><p>Structures of proteins in complex with proteins, DNA, or RNA molecules were obtained from the PDB and PISA database (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/pdbe/pisa/" id="intref0025">http://www.ebi.ac.uk/pdbe/pisa/</ext-link>). Interface residues were identified and their positions converted into Ensembl protein coordinates. PISA residue densities were calculated by counting unique positions and dividing by protein lengths. Differences in the distributions of interface-forming PISA residue densities were analyzed as before. Biological process and protein class enrichments for parent genes that donate ten or more interface-forming residues to fusion proteins were calculated.</p></sec><sec id="sec4.11"><title>Analysis of Short Linear Peptide Motifs in Parents</title><p>A set of 1,410 experimentally validated (<xref rid="bib12" ref-type="bibr">Dinkel et&#x000a0;al., 2014</xref>) and 1,036,282 computationally predicted (<xref rid="bib14" ref-type="bibr">Doszt&#x000e1;nyi et&#x000a0;al., 2009</xref>) LMs were acquired and mapped onto proteins. LM densities were calculated by counting unique ELM accessions and dividing by protein length. Differences in LM density were assessed across parent gene sets and across included versus excluded segments. Due to the small sample size of experimentally verified LMs, functional enrichments were reported even if the number of genes in an enriched category was less than ten. Parent proteins that donate LMs to fusion proteins were assessed for functional enrichments.</p></sec><sec id="sec4.12"><title>Analysis of PTM Sites</title><p>PTM sites, which are candidate sites for regulating protein interactions, were acquired from the PTMcode v2 data set (<xref rid="bib33" ref-type="bibr">Minguez et&#x000a0;al., 2015</xref>). Differences in PTMcode site densities per gene were assessed for different parent gene sets and across included versus excluded segments. Further, we obtained and cleaned a data set of experimentally validated PTMs (dbPTM 3.0 database; <xref rid="bib28" ref-type="bibr">Lu et&#x000a0;al., 2013</xref>). PTM densities were analyzed as before at the whole protein and fusion segment level. Enrichments of specific types of modification sites were quantified in included and excluded segments.</p></sec><sec id="sec4.13"><title>Analysis of TF Fusions and the Expression Levels of Target Genes</title><p>Fusion transcripts in TCGA samples (<xref rid="bib55" ref-type="bibr">Yoshihara et&#x000a0;al., 2015</xref>) were filtered to identify fusions involving TFs (n&#x000a0;= 1,131) (<xref rid="mmc8" ref-type="supplementary-material">Table S7</xref>). The TCGA database (<xref rid="bib43" ref-type="bibr">Tomczak et&#x000a0;al., 2015</xref>) was queried to identify matched RNaseq data for TF fusion containing samples (n&#x000a0;= 29). Normalized expression counts for each matched sample pair were extracted, genes with extremely small read counts (n&#x000a0;&#x0003c; 10) removed, and DGE calculated as the absolute log<sub>2</sub> fold change between the diseased and healthy samples. The regulated target genes of TFs were acquired from the TRRUST database (<xref rid="bib17" ref-type="bibr">Han et&#x000a0;al., 2015</xref>). DGE values for the TF targets were compared against all other genes using non-parametric Wilcoxon rank-sum tests in cases where sufficient regulatory targets (n&#x000a0;&#x02265;&#x000a0;20) were available (n&#x000a0;= 8). The resulting p values were corrected for multiple testing using Holm&#x02019;s procedure.</p></sec></sec><sec id="sec5"><title>Author Contributions</title><p>Study Conception and Design: N.S.L., R.J.W., and M.M.B.; Acquisition of Data: N.S.L., L.M., M.E.O., J.G., and R.J.W.; Analysis and Interpretation of Data: N.S.L., L.M., M.B., R.J.W., T.F., and M.M.B.; Manuscript Writing: N.S.L. and M.M.B.; and Critical Inputs to Manuscript: N.S.L., L.M., T.F., M.E.O., R.J.W., M.B., and M.M.B. The project was led by N.S.L. and supervised by M.M.B.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Abate</surname><given-names>F.</given-names></name><name><surname>Zairis</surname><given-names>S.</given-names></name><name><surname>Ficarra</surname><given-names>E.</given-names></name><name><surname>Acquaviva</surname><given-names>A.</given-names></name><name><surname>Wiggins</surname><given-names>C.H.</given-names></name><name><surname>Frattini</surname><given-names>V.</given-names></name><name><surname>Lasorella</surname><given-names>A.</given-names></name><name><surname>Iavarone</surname><given-names>A.</given-names></name><name><surname>Inghirami</surname><given-names>G.</given-names></name><name><surname>Rabadan</surname><given-names>R.</given-names></name></person-group><article-title>Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer</article-title><source>BMC Syst. Biol.</source><volume>8</volume><year>2014</year><fpage>97</fpage><pub-id pub-id-type="pmid">25183062</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Blomen</surname><given-names>V.A.</given-names></name><name><surname>M&#x000e1;jek</surname><given-names>P.</given-names></name><name><surname>Jae</surname><given-names>L.T.</given-names></name><name><surname>Bigenzahn</surname><given-names>J.W.</given-names></name><name><surname>Nieuwenhuis</surname><given-names>J.</given-names></name><name><surname>Staring</surname><given-names>J.</given-names></name><name><surname>Sacco</surname><given-names>R.</given-names></name><name><surname>van Diemen</surname><given-names>F.R.</given-names></name><name><surname>Olk</surname><given-names>N.</given-names></name><name><surname>Stukalov</surname><given-names>A.</given-names></name></person-group><article-title>Gene essentiality and synthetic lethality in haploid human cells</article-title><source>Science</source><volume>350</volume><year>2015</year><fpage>1092</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">26472760</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Boisvert</surname><given-names>F.-M.</given-names></name><name><surname>Ahmad</surname><given-names>Y.</given-names></name><name><surname>Gierli&#x00144;ski</surname><given-names>M.</given-names></name><name><surname>Charri&#x000e8;re</surname><given-names>F.</given-names></name><name><surname>Lamont</surname><given-names>D.</given-names></name><name><surname>Scott</surname><given-names>M.</given-names></name><name><surname>Barton</surname><given-names>G.</given-names></name><name><surname>Lamond</surname><given-names>A.I.</given-names></name><name><surname>Gierlinski</surname><given-names>M.</given-names></name><name><surname>Charriere</surname><given-names>F.</given-names></name></person-group><article-title>A quantitative spatial proteomics analysis of proteome turnover in human cells</article-title><source>Mol. Cell. Proteomics</source><volume>11</volume><year>2012</year><comment>M111.011429</comment></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Bondeson</surname><given-names>D.P.</given-names></name><name><surname>Mares</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>I.E.D.</given-names></name><name><surname>Ko</surname><given-names>E.</given-names></name><name><surname>Campos</surname><given-names>S.</given-names></name><name><surname>Miah</surname><given-names>A.H.</given-names></name><name><surname>Mulholland</surname><given-names>K.E.</given-names></name><name><surname>Routly</surname><given-names>N.</given-names></name><name><surname>Buckley</surname><given-names>D.L.</given-names></name><name><surname>Gustafson</surname><given-names>J.L.</given-names></name></person-group><article-title>Catalytic in&#x000a0;vivo protein knockdown by small-molecule PROTACs</article-title><source>Nat. Chem. Biol.</source><volume>11</volume><year>2015</year><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">26075522</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Bossi</surname><given-names>A.</given-names></name><name><surname>Lehner</surname><given-names>B.</given-names></name></person-group><article-title>Tissue specificity and the human protein interaction network</article-title><source>Mol. Syst. Biol.</source><volume>5</volume><year>2009</year><fpage>260</fpage><pub-id pub-id-type="pmid">19357639</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Buljan</surname><given-names>M.</given-names></name><name><surname>Chalancon</surname><given-names>G.</given-names></name><name><surname>Eustermann</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>G.P.</given-names></name><name><surname>Fuxreiter</surname><given-names>M.</given-names></name><name><surname>Bateman</surname><given-names>A.</given-names></name><name><surname>Babu</surname><given-names>M.M.</given-names></name></person-group><article-title>Tissue-specific splicing of disordered segments that embed binding motifs rewires protein interaction networks</article-title><source>Mol. Cell</source><volume>46</volume><year>2012</year><fpage>871</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">22749400</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Charloteaux</surname><given-names>B.</given-names></name><name><surname>Zhong</surname><given-names>Q.</given-names></name><name><surname>Dreze</surname><given-names>M.</given-names></name><name><surname>Cusick</surname><given-names>M.E.</given-names></name><name><surname>Hill</surname><given-names>D.E.</given-names></name><name><surname>Vidal</surname><given-names>M.</given-names></name></person-group><article-title>Protein-protein interactions and networks: forward and reverse edgetics</article-title><source>Methods Mol. Biol.</source><volume>759</volume><year>2011</year><fpage>197</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">21863489</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Cierpicki</surname><given-names>T.</given-names></name><name><surname>Grembecka</surname><given-names>J.</given-names></name></person-group><article-title>Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?</article-title><source>Immunol. Rev.</source><volume>263</volume><year>2015</year><fpage>279</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">25510283</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Jaramillo</surname><given-names>M.</given-names></name><name><surname>Bari</surname><given-names>H.</given-names></name><name><surname>Awan</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Connor-McCourt</surname><given-names>M.</given-names></name></person-group><article-title>A map of human cancer signaling</article-title><source>Mol. Syst. Biol.</source><volume>3</volume><year>2007</year><fpage>152</fpage><pub-id pub-id-type="pmid">18091723</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>N.E.</given-names></name><name><surname>Van Roey</surname><given-names>K.</given-names></name><name><surname>Weatheritt</surname><given-names>R.J.</given-names></name><name><surname>Toedt</surname><given-names>G.</given-names></name><name><surname>Uyar</surname><given-names>B.</given-names></name><name><surname>Altenberg</surname><given-names>B.</given-names></name><name><surname>Budd</surname><given-names>A.</given-names></name><name><surname>Diella</surname><given-names>F.</given-names></name><name><surname>Dinkel</surname><given-names>H.</given-names></name><name><surname>Gibson</surname><given-names>T.J.</given-names></name></person-group><article-title>Attributes of short linear motifs</article-title><source>Mol. Biosyst.</source><volume>8</volume><year>2012</year><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">21909575</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>David</surname><given-names>A.</given-names></name><name><surname>Razali</surname><given-names>R.</given-names></name><name><surname>Wass</surname><given-names>M.N.</given-names></name><name><surname>Sternberg</surname><given-names>M.J.E.</given-names></name></person-group><article-title>Protein-protein interaction sites are hot spots for disease-associated nonsynonymous SNPs</article-title><source>Hum. Mutat.</source><volume>33</volume><year>2012</year><fpage>359</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">22072597</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Dinkel</surname><given-names>H.</given-names></name><name><surname>Van Roey</surname><given-names>K.</given-names></name><name><surname>Michael</surname><given-names>S.</given-names></name><name><surname>Davey</surname><given-names>N.E.</given-names></name><name><surname>Weatheritt</surname><given-names>R.J.</given-names></name><name><surname>Born</surname><given-names>D.</given-names></name><name><surname>Speck</surname><given-names>T.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>D.</given-names></name><name><surname>Grebnev</surname><given-names>G.</given-names></name><name><surname>Kuban</surname><given-names>M.</given-names></name></person-group><article-title>The eukaryotic linear motif resource ELM: 10 years and counting</article-title><source>Nucleic Acids Res.</source><volume>42</volume><year>2014</year><fpage>D259</fpage><lpage>D266</lpage><pub-id pub-id-type="pmid">24214962</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Doszt&#x000e1;nyi</surname><given-names>Z.</given-names></name><name><surname>Csizmok</surname><given-names>V.</given-names></name><name><surname>Tompa</surname><given-names>P.</given-names></name><name><surname>Simon</surname><given-names>I.</given-names></name></person-group><article-title>IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content</article-title><source>Bioinformatics</source><volume>21</volume><year>2005</year><fpage>3433</fpage><lpage>3434</lpage><pub-id pub-id-type="pmid">15955779</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Doszt&#x000e1;nyi</surname><given-names>Z.</given-names></name><name><surname>M&#x000e9;sz&#x000e1;ros</surname><given-names>B.</given-names></name><name><surname>Simon</surname><given-names>I.</given-names></name></person-group><article-title>ANCHOR: web server for predicting protein binding regions in disordered proteins</article-title><source>Bioinformatics</source><volume>25</volume><year>2009</year><fpage>2745</fpage><lpage>2746</lpage><pub-id pub-id-type="pmid">19717576</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Frenkel-Morgenstern</surname><given-names>M.</given-names></name><name><surname>Gorohovski</surname><given-names>A.</given-names></name><name><surname>Lacroix</surname><given-names>V.</given-names></name><name><surname>Rogers</surname><given-names>M.</given-names></name><name><surname>Ibanez</surname><given-names>K.</given-names></name><name><surname>Boullosa</surname><given-names>C.</given-names></name><name><surname>Andres Leon</surname><given-names>E.</given-names></name><name><surname>Ben-Hur</surname><given-names>A.</given-names></name><name><surname>Valencia</surname><given-names>A.</given-names></name></person-group><article-title>ChiTaRS: a database of human, mouse and fruit fly chimeric transcripts and RNA-sequencing data</article-title><source>Nucleic Acids Res.</source><volume>41</volume><year>2013</year><fpage>D142</fpage><lpage>D151</lpage><pub-id pub-id-type="pmid">23143107</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Gianni</surname><given-names>M.</given-names></name><name><surname>Boldetti</surname><given-names>A.</given-names></name><name><surname>Guarnaccia</surname><given-names>V.</given-names></name><name><surname>Rambaldi</surname><given-names>A.</given-names></name><name><surname>Parrella</surname><given-names>E.</given-names></name><name><surname>Raska</surname><given-names>I.</given-names><suffix>Jr.</suffix></name><name><surname>Rochette-Egly</surname><given-names>C.</given-names></name><name><surname>Del Sal</surname><given-names>G.</given-names></name><name><surname>Rustighi</surname><given-names>A.</given-names></name><name><surname>Terao</surname><given-names>M.</given-names></name><name><surname>Garattini</surname><given-names>E.</given-names></name></person-group><article-title>Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha</article-title><source>Cancer Res.</source><volume>69</volume><year>2009</year><fpage>1016</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">19155306</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H.</given-names></name><name><surname>Shim</surname><given-names>H.</given-names></name><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Shim</surname><given-names>J.E.</given-names></name><name><surname>Ko</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>T.</given-names></name></person-group><article-title>TRRUST: a reference database of human transcriptional regulatory interactions</article-title><source>Sci. Rep.</source><volume>5</volume><year>2015</year><fpage>11432</fpage><pub-id pub-id-type="pmid">26066708</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Hegyi</surname><given-names>H.</given-names></name><name><surname>Buday</surname><given-names>L.</given-names></name><name><surname>Tompa</surname><given-names>P.</given-names></name></person-group><article-title>Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins</article-title><source>PLoS Comput. Biol.</source><volume>5</volume><year>2009</year><fpage>e1000552</fpage><pub-id pub-id-type="pmid">19888473</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>H&#x000f6;glund</surname><given-names>M.</given-names></name><name><surname>Frigyesi</surname><given-names>A.</given-names></name><name><surname>Mitelman</surname><given-names>F.</given-names></name></person-group><article-title>A gene fusion network in human neoplasia</article-title><source>Oncogene</source><volume>25</volume><year>2006</year><fpage>2674</fpage><lpage>2678</lpage><pub-id pub-id-type="pmid">16331252</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.-G.</given-names></name></person-group><article-title>Regulation of TGF-&#x003b2; receptor activity</article-title><source>Cell Biosci.</source><volume>2</volume><year>2012</year><fpage>9</fpage><pub-id pub-id-type="pmid">22420375</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Huttlin</surname><given-names>E.L.</given-names></name><name><surname>Ting</surname><given-names>L.</given-names></name><name><surname>Bruckner</surname><given-names>R.J.</given-names></name><name><surname>Gebreab</surname><given-names>F.</given-names></name><name><surname>Gygi</surname><given-names>M.P.</given-names></name><name><surname>Szpyt</surname><given-names>J.</given-names></name><name><surname>Tam</surname><given-names>S.</given-names></name><name><surname>Zarraga</surname><given-names>G.</given-names></name><name><surname>Colby</surname><given-names>G.</given-names></name><name><surname>Baltier</surname><given-names>K.</given-names></name></person-group><article-title>The BioPlex Network: A systematic exploration of the human interactome</article-title><source>Cell</source><volume>162</volume><year>2015</year><fpage>425</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">26186194</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Fang</surname><given-names>G.</given-names></name></person-group><article-title>Targeting protein-protein interaction by small molecules</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><volume>54</volume><year>2014</year><fpage>435</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">24160698</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Jividen</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Chimeric RNAs generated by intergenic splicing in normal and cancer cells</article-title><source>Genes Chromosomes Cancer</source><volume>53</volume><year>2014</year><fpage>963</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">25131334</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Kuenemann</surname><given-names>M.A.</given-names></name><name><surname>Sperandio</surname><given-names>O.</given-names></name><name><surname>Labb&#x000e9;</surname><given-names>C.M.</given-names></name><name><surname>Lagorce</surname><given-names>D.</given-names></name><name><surname>Miteva</surname><given-names>M.A.</given-names></name><name><surname>Villoutreix</surname><given-names>B.O.</given-names></name></person-group><article-title>In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances</article-title><source>Prog. Biophys. Mol. Biol.</source><volume>119</volume><year>2015</year><fpage>20</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">25748546</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Kumar-Sinha</surname><given-names>C.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group><article-title>Landscape of gene fusions in epithelial cancers: seq and ye shall find</article-title><source>Genome Med.</source><volume>7</volume><year>2015</year><fpage>129</fpage><pub-id pub-id-type="pmid">26684754</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Latysheva</surname><given-names>N.S.</given-names></name><name><surname>Babu</surname><given-names>M.M.</given-names></name></person-group><article-title>Discovering and understanding oncogenic gene fusions through data intensive computational approaches</article-title><source>Nucleic Acids Res.</source><volume>44</volume><year>2016</year><fpage>4487</fpage><lpage>4503</lpage><pub-id pub-id-type="pmid">27105842</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Lobato</surname><given-names>M.N.</given-names></name><name><surname>Metzler</surname><given-names>M.</given-names></name><name><surname>Drynan</surname><given-names>L.</given-names></name><name><surname>Forster</surname><given-names>A.</given-names></name><name><surname>Pannell</surname><given-names>R.</given-names></name><name><surname>Rabbitts</surname><given-names>T.H.</given-names></name></person-group><article-title>Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias</article-title><source>J.&#x000a0;Natl. Cancer Inst. Monogr.</source><volume>39</volume><year>2008</year><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18648005</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.-T.</given-names></name><name><surname>Huang</surname><given-names>K.-Y.</given-names></name><name><surname>Su</surname><given-names>M.-G.</given-names></name><name><surname>Lee</surname><given-names>T.-Y.</given-names></name><name><surname>Breta&#x000f1;a</surname><given-names>N.A.</given-names></name><name><surname>Chang</surname><given-names>W.-C.</given-names></name><name><surname>Chen</surname><given-names>Y.-J.</given-names></name><name><surname>Chen</surname><given-names>Y.-J.</given-names></name><name><surname>Huang</surname><given-names>H.-D.</given-names></name></person-group><article-title>DbPTM 3.0: an informative resource for investigating substrate site specificity and functional association of protein post-translational modifications</article-title><source>Nucleic Acids Res.</source><volume>41</volume><year>2013</year><fpage>D295</fpage><lpage>D305</lpage><pub-id pub-id-type="pmid">23193290</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>F.</given-names></name><name><surname>Johansson</surname><given-names>B.</given-names></name><name><surname>Fioretos</surname><given-names>T.</given-names></name><name><surname>Mitelman</surname><given-names>F.</given-names></name></person-group><article-title>The emerging complexity of gene fusions in cancer</article-title><source>Nat. Rev. Cancer</source><volume>15</volume><year>2015</year><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">25998716</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>F.</given-names></name><name><surname>Antonescu</surname><given-names>C.R.</given-names></name><name><surname>Mitelman</surname><given-names>F.</given-names></name></person-group><article-title>Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes</article-title><source>Genes Chromosomes Cancer</source><volume>55</volume><year>2015</year><fpage>291</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">26684580</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>M.J.</given-names></name><name><surname>Das</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>INstruct: a database of high-quality 3D structurally resolved protein interactome networks</article-title><source>Bioinformatics</source><volume>29</volume><year>2013</year><fpage>1577</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">23599502</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>H.</given-names></name><name><surname>Muruganujan</surname><given-names>A.</given-names></name><name><surname>Casagrande</surname><given-names>J.T.</given-names></name><name><surname>Thomas</surname><given-names>P.D.</given-names></name></person-group><article-title>Large-scale gene function analysis with the PANTHER classification system</article-title><source>Nat. Protoc.</source><volume>8</volume><year>2013</year><fpage>1551</fpage><lpage>1566</lpage><pub-id pub-id-type="pmid">23868073</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Minguez</surname><given-names>P.</given-names></name><name><surname>Letunic</surname><given-names>I.</given-names></name><name><surname>Parca</surname><given-names>L.</given-names></name><name><surname>Garcia-Alonso</surname><given-names>L.</given-names></name><name><surname>Dopazo</surname><given-names>J.</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J.</given-names></name><name><surname>Bork</surname><given-names>P.</given-names></name></person-group><article-title>PTMcode v2: a resource for functional associations of post-translational modifications within and between proteins</article-title><source>Nucleic Acids Res.</source><volume>43</volume><year>2015</year><fpage>D494</fpage><lpage>D502</lpage><pub-id pub-id-type="pmid">25361965</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F.</given-names></name><name><surname>Johansson</surname><given-names>B.</given-names></name><name><surname>Mertens</surname><given-names>F.</given-names></name></person-group><article-title>The impact of translocations and gene fusions on cancer causation</article-title><source>Nat. Rev. Cancer</source><volume>7</volume><year>2007</year><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">17361217</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>R.K.</given-names></name><name><surname>Sugar</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Klotz</surname><given-names>L.H.</given-names></name><name><surname>Yang</surname><given-names>L.-Y.</given-names></name><name><surname>Stanimirovic</surname><given-names>A.</given-names></name><name><surname>Encioiu</surname><given-names>E.</given-names></name><name><surname>Neill</surname><given-names>M.</given-names></name><name><surname>Loblaw</surname><given-names>D.A.</given-names></name></person-group><article-title>Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer</article-title><source>Br. J. Cancer</source><volume>97</volume><year>2007</year><fpage>1690</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">17971772</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Oates</surname><given-names>M.E.</given-names></name><name><surname>Romero</surname><given-names>P.</given-names></name><name><surname>Ishida</surname><given-names>T.</given-names></name><name><surname>Ghalwash</surname><given-names>M.</given-names></name><name><surname>Mizianty</surname><given-names>M.J.</given-names></name><name><surname>Xue</surname><given-names>B.</given-names></name><name><surname>Doszt&#x000e1;nyi</surname><given-names>Z.</given-names></name><name><surname>Uversky</surname><given-names>V.N.</given-names></name><name><surname>Obradovic</surname><given-names>Z.</given-names></name><name><surname>Kurgan</surname><given-names>L.</given-names></name></person-group><article-title>D<sup>2</sup>P<sup>2</sup>: database of disordered protein predictions</article-title><source>Nucleic Acids Res.</source><volume>41</volume><year>2013</year><fpage>D508</fpage><lpage>D516</lpage><pub-id pub-id-type="pmid">23203878</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Pawson</surname><given-names>T.</given-names></name><name><surname>Warner</surname><given-names>N.</given-names></name></person-group><article-title>Oncogenic re-wiring of cellular signaling pathways</article-title><source>Oncogene</source><volume>26</volume><year>2007</year><fpage>1268</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">17322911</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D.R.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Y.-M.</given-names></name><name><surname>Shankar</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Ateeq</surname><given-names>B.</given-names></name><name><surname>Asangani</surname><given-names>I.A.</given-names></name><name><surname>Iyer</surname><given-names>M.</given-names></name><name><surname>Maher</surname><given-names>C.A.</given-names></name><name><surname>Grasso</surname><given-names>C.S.</given-names></name></person-group><article-title>Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer</article-title><source>Nat. Med.</source><volume>17</volume><year>2011</year><fpage>1646</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">22101766</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Rolland</surname><given-names>T.</given-names></name><name><surname>Ta&#x0015f;an</surname><given-names>M.</given-names></name><name><surname>Charloteaux</surname><given-names>B.</given-names></name><name><surname>Pevzner</surname><given-names>S.J.</given-names></name><name><surname>Zhong</surname><given-names>Q.</given-names></name><name><surname>Sahni</surname><given-names>N.</given-names></name><name><surname>Yi</surname><given-names>S.</given-names></name><name><surname>Lemmens</surname><given-names>I.</given-names></name><name><surname>Fontanillo</surname><given-names>C.</given-names></name><name><surname>Mosca</surname><given-names>R.</given-names></name></person-group><article-title>A proteome-scale map of the human interactome network</article-title><source>Cell</source><volume>159</volume><year>2014</year><fpage>1212</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">25416956</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Shugay</surname><given-names>M.</given-names></name><name><surname>Ortiz de Mend&#x000ed;bil</surname><given-names>I.</given-names></name><name><surname>Vizmanos</surname><given-names>J.L.</given-names></name><name><surname>Novo</surname><given-names>F.J.</given-names></name></person-group><article-title>Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions</article-title><source>Bioinformatics</source><volume>29</volume><year>2013</year><fpage>2539</fpage><lpage>2546</lpage><pub-id pub-id-type="pmid">23956304</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Sudha</surname><given-names>G.</given-names></name><name><surname>Nussinov</surname><given-names>R.</given-names></name><name><surname>Srinivasan</surname><given-names>N.</given-names></name></person-group><article-title>An overview of recent advances in structural bioinformatics of protein-protein interactions and a guide to their principles</article-title><source>Prog. Biophys. Mol. Biol.</source><volume>116</volume><year>2014</year><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">25077409</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Tognon</surname><given-names>C.E.</given-names></name><name><surname>Somasiri</surname><given-names>A.M.</given-names></name><name><surname>Evdokimova</surname><given-names>V.E.</given-names></name><name><surname>Trigo</surname><given-names>G.</given-names></name><name><surname>Uy</surname><given-names>E.E.</given-names></name><name><surname>Melnyk</surname><given-names>N.</given-names></name><name><surname>Carboni</surname><given-names>J.M.</given-names></name><name><surname>Gottardis</surname><given-names>M.M.</given-names></name><name><surname>Roskelley</surname><given-names>C.D.</given-names></name><name><surname>Pollak</surname><given-names>M.</given-names></name><name><surname>Sorensen</surname><given-names>P.H.</given-names></name></person-group><article-title>ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway</article-title><source>Cancer Res.</source><volume>71</volume><year>2011</year><fpage>1060</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">21148487</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Tomczak</surname><given-names>K.</given-names></name><name><surname>Czerwi&#x00144;ska</surname><given-names>P.</given-names></name><name><surname>Wiznerowicz</surname><given-names>M.</given-names></name></person-group><article-title>The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title><source>Contemp. Oncol. (Pozn.)</source><volume>19</volume><issue>1A</issue><year>2015</year><fpage>A68</fpage><lpage>A77</lpage><pub-id pub-id-type="pmid">25691825</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Tompa</surname><given-names>P.</given-names></name><name><surname>Davey</surname><given-names>N.E.</given-names></name><name><surname>Gibson</surname><given-names>T.J.</given-names></name><name><surname>Babu</surname><given-names>M.M.</given-names></name></person-group><article-title>A million peptide motifs for the molecular biologist</article-title><source>Mol. Cell</source><volume>55</volume><year>2014</year><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">25038412</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Van Roey</surname><given-names>K.</given-names></name><name><surname>Dinkel</surname><given-names>H.</given-names></name><name><surname>Weatheritt</surname><given-names>R.J.</given-names></name><name><surname>Gibson</surname><given-names>T.J.</given-names></name><name><surname>Davey</surname><given-names>N.E.</given-names></name></person-group><article-title>The switches.ELM resource: a compendium of conditional regulatory interaction interfaces</article-title><source>Sci. Signal.</source><volume>6</volume><year>2013</year><fpage>rs7</fpage><pub-id pub-id-type="pmid">23550212</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Varley</surname><given-names>K.E.</given-names></name><name><surname>Gertz</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>B.S.</given-names></name><name><surname>Davis</surname><given-names>N.S.</given-names></name><name><surname>Bowling</surname><given-names>K.M.</given-names></name><name><surname>Kirby</surname><given-names>M.K.</given-names></name><name><surname>Nesmith</surname><given-names>A.S.</given-names></name><name><surname>Oliver</surname><given-names>P.G.</given-names></name><name><surname>Grizzle</surname><given-names>W.E.</given-names></name><name><surname>Forero</surname><given-names>A.</given-names></name></person-group><article-title>Recurrent read-through fusion transcripts in breast cancer</article-title><source>Breast Cancer Res. Treat.</source><volume>146</volume><year>2014</year><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">24929677</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Vitari</surname><given-names>A.C.</given-names></name><name><surname>Leong</surname><given-names>K.G.</given-names></name><name><surname>Newton</surname><given-names>K.</given-names></name><name><surname>Yee</surname><given-names>C.</given-names></name><name><surname>O&#x02019;Rourke</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Phu</surname><given-names>L.</given-names></name><name><surname>Vij</surname><given-names>R.</given-names></name><name><surname>Ferrando</surname><given-names>R.</given-names></name><name><surname>Couto</surname><given-names>S.S.</given-names></name></person-group><article-title>COP1 is a tumour suppressor that causes degradation of ETS transcription factors</article-title><source>Nature</source><volume>474</volume><year>2011</year><fpage>403</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">21572435</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>C.</given-names></name><name><surname>Abreu</surname><given-names>R. de S.</given-names></name><name><surname>Ko</surname><given-names>D.</given-names></name><name><surname>Le</surname><given-names>S.-Y.</given-names></name><name><surname>Shapiro</surname><given-names>B.A.</given-names></name><name><surname>Burns</surname><given-names>S.C.</given-names></name><name><surname>Sandhu</surname><given-names>D.</given-names></name><name><surname>Boutz</surname><given-names>D.R.</given-names></name><name><surname>Marcotte</surname><given-names>E.M.</given-names></name><name><surname>Penalva</surname><given-names>L.O.</given-names></name></person-group><article-title>Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line</article-title><source>Mol. Syst. Biol.</source><volume>6</volume><year>2010</year><fpage>400</fpage><pub-id pub-id-type="pmid">20739923</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Gulbahce</surname><given-names>N.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Network-based methods for human disease gene prediction</article-title><source>Brief. Funct. Genomics</source><volume>10</volume><year>2011</year><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">21764832</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Thijssen</surname><given-names>B.</given-names></name><name><surname>Das</surname><given-names>J.</given-names></name><name><surname>Lipkin</surname><given-names>S.M.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Three-dimensional reconstruction of protein networks provides insight into human genetic disease</article-title><source>Nat. Biotechnol.</source><volume>30</volume><year>2012</year><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">22252508</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Sahni</surname><given-names>N.</given-names></name><name><surname>Vidal</surname><given-names>M.</given-names></name></person-group><article-title>Global edgetic rewiring in cancer networks</article-title><source>Cell Syst.</source><volume>1</volume><year>2015</year><fpage>251</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">27136053</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>I.R.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Futreal</surname><given-names>P.A.</given-names></name><name><surname>Chin</surname><given-names>L.</given-names></name></person-group><article-title>Emerging patterns of somatic mutations in cancer</article-title><source>Nat. Rev. Genet.</source><volume>14</volume><year>2013</year><fpage>703</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">24022702</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>G.E.</given-names></name><name><surname>Buckley</surname><given-names>D.L.</given-names></name><name><surname>Paulk</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>J.M.</given-names></name><name><surname>Souza</surname><given-names>A.</given-names></name><name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name><name><surname>Bradner</surname><given-names>J.E.</given-names></name></person-group><article-title>Drug Development. Phthalimide conjugation as a strategy for in&#x000a0;vivo target protein degradation</article-title><source>Science</source><volume>348</volume><year>2015</year><fpage>1376</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">25999370</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Stein</surname><given-names>L.</given-names></name></person-group><article-title>A human functional protein interaction network and its application to cancer data analysis</article-title><source>Genome Biol.</source><volume>11</volume><year>2010</year><fpage>R53</fpage><pub-id pub-id-type="pmid">20482850</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Yoshihara</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Torres-Garcia</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Vegesna</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.W.</given-names></name></person-group><article-title>The landscape and therapeutic relevance of cancer-associated transcript fusions</article-title><source>Oncogene</source><volume>34</volume><year>2015</year><fpage>4845</fpage><lpage>4854</lpage><pub-id pub-id-type="pmid">25500544</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C.-Y.</given-names></name><name><surname>Liu</surname><given-names>H.-J.</given-names></name><name><surname>Hung</surname><given-names>L.-Y.</given-names></name><name><surname>Kuo</surname><given-names>H.-C.</given-names></name><name><surname>Chuang</surname><given-names>T.-J.</given-names></name></person-group><article-title>Is an observed non-co-linear RNA product spliced in trans, in cis or just in&#x000a0;vitro?</article-title><source>Nucleic Acids Res.</source><volume>42</volume><year>2014</year><fpage>9410</fpage><lpage>9423</lpage><pub-id pub-id-type="pmid">25053845</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>M.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>H.G.</given-names></name><name><surname>Frierson</surname><given-names>H.F.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation</article-title><source>Cancer Discov.</source><volume>2</volume><year>2012</year><fpage>598</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">22719019</pub-id></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Supplemental Experimental Procedures and Figures S1&#x02013;S7</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Table S1. Fusion Proteins and Parent Functions, Related to Figure&#x000a0;1</title><p>The table shows a description of fusion proteins used in this study and biological process and protein class enrichments of parent genes. The gene symbols in the original ChiTaRS mapping can differ from gene names associated with mapped Ensembl proteins (see Supplemental Information), and we provide both gene name sets in the fusion protein listing (see the fusion protein mapping web server <ext-link ext-link-type="uri" xlink:href="http://www.fusion.d2p2.pro/" id="intref0035">http://www.fusion.d2p2.pro/</ext-link> for further details).</p></caption><media xlink:href="mmc2.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><title>Table S2. Functions of the Top Quartile Centrality Genes, Related to Figure&#x000a0;2</title><p>The table shows the biological process and protein class enrichments of parent and non-parent genes with the highest PPI network centralities.</p></caption><media xlink:href="mmc3.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc4"><caption><title>Table S3. Tissue-Specific Network Centrality, Related to Figure&#x000a0;2</title><p>The table shows the averaged network centrality measures for parent and non-parent proteins in tissue-specific interaction networks.</p></caption><media xlink:href="mmc4.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc5"><caption><title>Table S4. Interaction-Mediating Domains in Fusion Proteins and Parent Functions, Related to Figure&#x000a0;3</title><p>The table shows IMD residues incorporated into fusion proteins and biological process and protein class enrichments of parent genes that donate &#x02265;20% of an IMD.</p></caption><media xlink:href="mmc5.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc6"><caption><title>Table S5. Retained and Novel PPI Arising from Fusion-Mediated Domain Recombination, Related to Figure&#x000a0;4</title><p>The table shows the retained and novel PPIs resulting from the transfer of largely intact (&#x02265;90% of the domain sequence) IMD into fusion proteins.</p></caption><media xlink:href="mmc6.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc7"><caption><title>Table S6. Interfaces, Linear Motifs, and PTMs in Fusion Proteins and Parent Functions, Related to Figure&#x000a0;3</title><p>The table shows structural interfaces of protein complexes that are incorporated into fusion proteins and biological process and protein class enrichments of parent genes that donate ten or more interface forming residues; experimentally validated short linear peptide motifs incorporated into fusion proteins and biological process and protein class enrichments of parent genes that donate at least one such linear motif; and experimentally validated PTMs incorporated into fusion proteins. Also, biological process and protein class enrichments for parent genes that either retain or lose &#x02265;90% of their PTM content upon fusion. Certain PTM types were found to occur in both included and excluded segments more frequently than expected given the global frequencies of all known PTMs, such as S-Nitrosylation (1.7&#x000d7; enrichment in included segments and 1.6&#x000d7; in excluded segments). Other PTM types showed differential presence/absence patterns based on segment inclusion: methylation sites are more highly enriched in included segments (3.5&#x000d7; enrichment) than in excluded segments (2.5&#x000d7;), as are acetylation sites (1.8&#x000d7; included and 1.3&#x000d7; excluded). Interestingly, both N-linked and O-linked glycosylation, which are involved in protein folding and stability and cancer processes like migration and invasion, are generally depleted in parent proteins.</p></caption><media xlink:href="mmc7.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc8"><caption><title>Table S7. Fusion-Mediated Deregulation of TF Target Genes, Related to Figure&#x000a0;6</title><p>The table shows a differential expression analysis of breast cancer samples containing fusion transcripts composed of at least one TF parent. The differential gene expression values of the TF targets were compared to those of all other genes.</p></caption><media xlink:href="mmc8.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc9"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc9.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We thank A. Krishnan, A. Bateman, B. Luisi, C. Ravarani, G. Chalancon, and S. Chavali for helpful discussions and feedback on the manuscript and M. Frenkel-Morgenstern for providing genomic coordinates from the ChiTaRS database for fusion protein mapping. This work was supported by the Medical Research Council (MC_U105185859 to M.M.B., N.S.L., L.M., R.J.W., and T.F and MC-A025-5PK11-6801 to M.B.), the Human Frontier Science Program (RGY0073/2010 to M.B. and M.M.B.), the Boehringer Ingelheim Fond (to T.F.), the Canadian Institute of Health Research (to R.J.W.), the IOF Marie Curie Fellowship (to R.J.W.), and the Lister Institute Research Prize Fellowship (to M.M.B.). We apologize for not being able to cite several relevant papers on this topic due to space constraints. We have extensively discussed a number of important papers in <xref rid="bib26" ref-type="bibr">Latysheva and Babu (2016)</xref>.</p></ack><fn-group><fn id="app1" fn-type="supplementary-material"><p>Supplemental Information includes Supplemental Experimental Procedures, seven figures, and seven tables and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.molcel.2016.07.008" id="intref0030">http://dx.doi.org/10.1016/j.molcel.2016.07.008</ext-link>.</p></fn></fn-group></back><floats-group><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Study Outline</p><p>(A) Investigating how gene fusions and fusion proteins could affect molecular interactions in cancer.</p><p>(B) Summary of analyses employed.</p><p>(C) Description of processing procedure applied to the ChiTaRS database of fusion (&#x0201c;chimeric&#x0201d;) mRNA sequences to obtain a data set of fusion proteins.</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figures S1</xref> and <xref rid="mmc1" ref-type="supplementary-material">S2</xref> and <xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Network Centrality of Parent Genes and Proteins</p><p>(A&#x02013;C) Parent genes possess more interaction partners in PPI networks (A), have higher betweenness centrality (B), and higher hub scores (C).</p><p>(D) PPIs involving parent proteins occur in more human tissues than interactions not involving parent proteins.</p><p>(E) The average number of interaction partners for parent proteins and all other proteins by tissue or cell type (gold&#x000a0;= blood, bone marrow, and lymph tissues and teal&#x000a0;= cancer cells). Throughout this study, distribution outliers are excluded from boxplots for presentation purposes, but included in statistical analyses.</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figures S3</xref> and <xref rid="mmc1" ref-type="supplementary-material">S4</xref> and <xref rid="mmc3" ref-type="supplementary-material">Tables S2</xref> and <xref rid="mmc4" ref-type="supplementary-material">S3</xref>.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Interaction-Mediating Molecular Features in Fusion Proteins</p><p>(A and B) IMDs in parent proteins (A) and fusion proteins (B).</p><p>(C and D) The PPI interface residues in parent proteins (C) and fusion proteins (D) are shown.</p><p>(E and F) The ELM LMs in parent proteins (E) and fusion proteins (F) are shown.</p><p>(G and H) The predicted ANCHOR LMs in parent proteins (G) and fusion proteins (H) are shown.</p><p>(I) The putative interaction-regulating PTMs in parent proteins are shown.</p><p>(J and K) Other PTM sites in parent proteins (J) and fusion proteins (K) are shown.</p><p>(L) The PTM type enrichments in included and excluded parent protein segments are shown. Within each subplot, Holm&#x02019;s sequential Bonferroni correction for multiple testing was applied.</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref> and <xref rid="mmc5" ref-type="supplementary-material">Tables S4</xref> and <xref rid="mmc7" ref-type="supplementary-material">S6</xref>.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Retained and Novel PPI in Fusion Proteins</p><p>(A) The repeated inclusion of large portions of specific IMDs in fusion proteins can lead to the retention of domain-mediated interactions or the creation of novel interaction-like links between proteins.</p><p>(B and C) Subsets of the recurrently retained domain-mediated PPIs (B) and novel links (C) are shown.</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref> and <xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Fusion-Induced UB Site Gain and Loss in Cancer-Associated Proteins</p><p>Fusion proteins involving OGs and TSGs can lead to the loss or gain of ubiquitination sites.</p><p>(A) Example of an OG losing UB sites upon fusion.</p><p>(B) Example of a TSG gaining UB sites upon fusion. The protein structure cartoons are of EWSR1 (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:2CPE" id="intref0040">2CPE</ext-link>), FLI1 (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:1FLI" id="intref0045">1FLI</ext-link>), and TGFB1 (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:1KLA" id="intref0050">1KLA</ext-link>).</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Molecular Principles by which Gene Fusions Can Alter Protein Interaction Networks in Cancer</p><p>(A) Fusion tends to involve highly central proteins in interaction networks and can alter networks by several mechanisms. Rewiring effects can play key roles in seemingly straightforward fusion events, as in the constitutive kinase activation found in the BCR-ABL1 fusion.</p><p>(B and C) More generally, fusion can affect molecular interactions of proteins by shuffling interaction-prone regions within ordered (B) and disordered (C) protein segments.</p><p>See also <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S7</xref> and <xref rid="mmc8" ref-type="supplementary-material">Table S7</xref>.</p></caption><graphic xlink:href="gr6"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>OGs Losing &#x02265;5&#x000a0;UB Sites and Tumor Suppressor Genes Gaining &#x02265;5&#x000a0;UB Sites as a Result of Fusion Events</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Fusion Accession<xref rid="tblfn1" ref-type="table-fn">a</xref></th><th>OG</th><th>Description</th><th>Number of UB Sites Lost</th><th>Length of OG Retained Segment</th><th>Fusion Partner</th><th>Description of Fusion Partner</th></tr></thead><tbody><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BF736842" id="intref0055">BF736842</ext-link></td><td>EGFR</td><td>epidermal growth factor receptor</td><td align="char">17</td><td align="char">25</td><td>SLC12A9</td><td>solute carrier family 12, member 9</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:AK098472" id="intref0060">AK098472</ext-link></td><td>CTNNB1</td><td>catenin (cadherin-associated protein), beta 1, and 88&#x000a0;kDa</td><td align="char">9</td><td align="char">420</td><td>RP11-345J4.5</td><td>bolA-like protein 2</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BE176861" id="intref0065">BE176861</ext-link></td><td>COPS5</td><td>COP9 signalosome subunit 5</td><td align="char">9</td><td align="char">112</td><td>HNRNPH3</td><td>heterogeneous nuclear ribonucleoprotein H3 (2H9)</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BE176782" id="intref0070">BE176782</ext-link></td><td>COPS5</td><td>COP9 signalosome subunit 5</td><td align="char">9</td><td align="char">112</td><td>HNRNPH3</td><td>heterogeneous nuclear ribonucleoprotein H3 (2H9)</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BG953255" id="intref0075">BG953255</ext-link></td><td>CTTN</td><td>cortactin</td><td align="char">9</td><td align="char">21</td><td>MYC</td><td>v-myc avian myelocytomatosis viral OG homolog</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BP430745" id="intref0080">BP430745</ext-link></td><td>CSE1L</td><td>CSE1 chromosome segregation 1-like (yeast)</td><td align="char">7</td><td align="char">41</td><td>UGP2</td><td>UDP-glucose pyrophosphorylase 2</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:CN278368" id="intref0085">CN278368</ext-link></td><td>TRIM32</td><td>tripartite motif-containing protein 32</td><td align="char">7</td><td align="char">36</td><td>DDX21</td><td>DEAD (Asp-Glu-Ala-Asp) box helicase 21</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:CV340327" id="intref0090">CV340327</ext-link></td><td>ERBB2</td><td>v-erb-b2 avian erythroblastic leukemia viral OG homolog 2</td><td align="char">6</td><td align="char">21</td><td>NOMO1</td><td>NODAL modulator 1</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BE273347" id="intref0095">BE273347</ext-link></td><td>DCUN1D1</td><td>DCN1, defective in cullin neddylation 1, and domain containing 1</td><td align="char">6</td><td align="char">24</td><td>QTRT1</td><td>queuine tRNA-ribosyltransferase 1</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BC001010" id="intref0100">BC001010</ext-link></td><td>CDK4</td><td>cyclin-dependent kinase 4</td><td align="char">6</td><td align="char">30</td><td>RPL4</td><td>ribosomal protein L4</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:AW371253" id="intref0105">AW371253</ext-link></td><td>ERBB2</td><td>v-erb-b2 avian erythroblastic leukemia viral OG homolog 2</td><td align="char">5</td><td align="char">49</td><td>RABGAP1</td><td>RAB GTPase activating protein 1</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:U08818" id="intref0110">U08818</ext-link></td><td>MET</td><td>met proto-OG</td><td align="char">5</td><td align="char">380</td><td>MIR548F1</td><td>microRNA 548f-1</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:U19348" id="intref0115">U19348</ext-link></td><td>MET</td><td>met proto-OG</td><td align="char">5</td><td align="char">380</td><td>MIR548F1</td><td>microRNA 548f-1</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:DA624159" id="intref0120">DA624159</ext-link></td><td>TFG</td><td>TRK-fused gene</td><td align="char">5</td><td align="char">90</td><td>GPR128</td><td>G protein-coupled receptor 128</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td><bold>Fusion Accession</bold></td><td><bold>Tumor Suppressor Gene</bold></td><td><bold>Description</bold></td><td><bold>Number of UB Sites Gained</bold></td><td><bold>Length of TSG Retained Segment</bold></td><td><bold>Fusion Partner</bold></td><td><bold>Description of Fusion Partner</bold></td></tr><tr><td colspan="7"><hr/></td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:CD368725" id="intref0125">CD368725</ext-link></td><td>TGFB1</td><td>transforming growth factor, beta 1</td><td align="char">13</td><td align="char">45</td><td>ATP50</td><td>ATP synthase, H<sup>+</sup> transporting, mitochondrial F1 Complex, and O subunit</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:DB041801" id="intref0130">DB041801</ext-link></td><td>SMARCA4</td><td>SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, and member 4</td><td align="char">9</td><td align="char">78</td><td>UBB</td><td>ubiquitin B</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BP213958" id="intref0135">BP213958</ext-link></td><td>ARID1A</td><td>AT rich interactive domain 1A (SWI-like)</td><td align="char">6</td><td align="char">34</td><td>DNAJA2</td><td>DnaJ (Hsp40) homolog, subfamily A, and member 2</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:DB120764" id="intref0140">DB120764</ext-link></td><td>EEF1A1</td><td>eukaryotic translation elongation factor 1 alpha 1</td><td align="char">6</td><td align="char">4</td><td>HIST1H2AM</td><td>histone cluster 1, H2am</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BG035867" id="intref0145">BG035867</ext-link></td><td>EIF1</td><td>eukaryotic translation initiation factor 1</td><td align="char">6</td><td align="char">38</td><td>RALY</td><td>RALY heterogeneous nuclear ribonucleoprotein</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:AB209020" id="intref0150">AB209020</ext-link></td><td>GJA1</td><td>gap junction protein, alpha 1, and 43&#x000a0;kDa</td><td align="char">6</td><td align="char">136</td><td>IFT140</td><td>intraflagellar transport 140</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BG926120" id="intref0155">BG926120</ext-link></td><td>PDCD4</td><td>programmed cell death 4 (neoplastic transformation inhibitor)</td><td align="char">5</td><td align="char">110</td><td>GAPDH</td><td>glyceraldehyde-3-phosphate dehydrogenase</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BC001412" id="intref0160">BC001412</ext-link></td><td>EEF1A1</td><td>eukaryotic translation elongation factor 1 alpha 1</td><td align="char">5</td><td align="char">462</td><td>LASP1</td><td>LIM and SH3 protein 1</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:BQ962146" id="intref0165">BQ962146</ext-link></td><td>E2F1</td><td>E2F TF 1</td><td align="char">5</td><td align="char">8</td><td>RDH11</td><td>retinol dehydrogenase 11 (all-<italic>trans</italic>/9-<italic>cis</italic>/11-<italic>cis</italic>)</td></tr><tr><td><ext-link ext-link-type="uri" xlink:href="ncbi-n:CK004088" id="intref0170">CK004088</ext-link></td><td>NDRG2</td><td>NDRG family member 2</td><td align="char">5</td><td align="char">153</td><td>RPL38</td><td>ribosomal protein L38</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p id="ntpara0010">ChiTaRS fusion event accessions are listed along with affected genes, retained segment lengths, and tallies of UB site gain or loss.</p></fn></table-wrap-foot></table-wrap></floats-group></article>